Many researchers have speculated that the clinical progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is driven by defects in dendritic cell (DC) function. Evidence supporting this assumption is, however, controversial and no mechanism for the putative DC dysfunction has so far been demonstrated. We studied DC subsets from the bone marrow of MM patients, in comparison to those of MGUS patients and control subjects. We found that myeloid DC (mDC) and plasmacytoid DC ( 
INTRODUCTION
Multiple myeloma (MM) is a lethal plasma cell malignancy that is often anticipated by a preneoplastic phase termed monoclonal gammopathy of undetermined significance (MGUS) 1 .
How MGUS progresses to MM is not exactly known, but it is thought to involve the generation of effective cytotoxic CD8 + T cell responses against tumor plasma cells. This generation relies on dendritic cells (DC), highly differentiated antigen-presenting cells with the unique capacity to internalize tumor antigens from the environment and present them as HLA class I-bound peptides (a process known as "cross-presentation") [2] [3] [4] .
In humans, DC circulating in the blood characteristically express high levels of HLA class II molecules and are proficient in antigen uptake and processing. However, they express low levels of HLA class I and co-stimulatory molecules (e.g. CD80, CD86) and lack common lineage markers such as CD3, CD14, CD16, CD19, CD20 and CD56. These lineage-negative DC detect and take up dead or dying tumor cells through the recognition of a variety of proteins, categorized as damage-associated molecular pattern molecules (DAMPs), expressed on the surface of such cells 6 . One of these molecules is the endoplasmic reticulum protein calreticulin, which has been shown to be translocated to the plasma membrane of apoptotic cells where it acts as an "eat-me signal" for DC by binding with CD91 [7] [8] [9] . Once DC engulf dead or dying tumor cells, they undergo a series of maturation events that reduce the antigencapturing capacity, increase the expression of HLA class I and II and co-stimulatory molecules, develop an exceptional efficiency in processing tumor proteins and presenting tumor peptides to T cells, and augment the secretion of cytokines modulating T cell
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From 4 activation. In particular, mDC are major producers of interleukin (IL)-12, while pDC are specialized in producing type I interferon (IFN) 10 .
The process of degrading tumor proteins into peptides that will be presented by HLA class I molecules to CD8 + T cells occurs in the proteasome 11 . In this cylindrical 26S proteolytic complex, some of the catalytic subunits can be exchanged in response to changing cellular environments. In particular, the β subunits Delta, Zeta, and MB1 can be replaced by the β i subunits LMP2, LMP7, and LMP10, respectively. In DC, a mixed population of proteasomes, some incorporating β subunits and others β i subunits, can be found.
There is no agreement in the literature about the role of DC in MM pathogenesis. Different studies have shown that DC may promote myeloma-specific T cell responses 12,13 while they may also support plasma cell proliferation and survival via engagement of their CD80/86
receptors by the ligand CD28 on plasma cells [14] [15] [16] [17] . Moreover, little information is available on DC in the bone marrow, which is the privileged site of clonal plasma cell proliferation and, therefore, the main site of tumor antigen expression.
In this study, we analyzed the ex vivo distribution as well as the phenotypic and functional features of mDC and pDC of MM patients, in comparison to those of MGUS patients and control subjects, and explored the immunological effects of interactions among DC, T cells and plasma cells within the bone marrow milieu.
For 
MATERIALS AND METHODS

Study subjects and biologic samples
Cell preparations
Peripheral blood (PB) and bone marrow (BM) samples, from patients and controls, were used to isolate mononuclear cells (PBMC and BMMC, respectively) by Ficoll-Paque Plus (GE Healthcare Life Sciences) density gradient centrifugation. From the PBMC and BMMC preparations, CD8 + T cells, mDC and pDC were purified by automated magnetic sorting using, respectively, anti-CD8 microbeads and BDCA-1 and BDCA-4 Isolation Kits (Miltenyi Biotec). For certain experiments, mDC were alternatively purified by negative selection using Myeloid Dendritic Cell Isolation Kit (Miltenyi Biotec). Bone marrow from patients was also used to directly isolate tumor plasma cells by automated magnetic cell sorting with anti-CD138 microbeads (Miltenyi Biotec). All sorted cell populations exhibited >95% purity, as revealed by flow cytometry on immunostained cells.
Tumor plasma cells were made apoptotic by γ -irradiation (50 Gy) and then used immediately in phagocytosis assays. Tumor plasma cell lysates were prepared as described previously 13 . K562 cells were purchased from ATCC.
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Immunofluorescence staining and fluorescent labeling of cells
A set of commercial and in-house monoclonal antibodies (mAb) was used. Fluorescein isothiocyanate (FITC)-conjugated Lineage mAb mix, phycoerythrin (PE)-cyanine 5 (Cy5)-conjugated anti-CD123 mAb, PE-Cy5-conjugated anti-CD11c mAb were purchased from BD Biosciences; PE-Texas red (ECD)-conjugated anti-HLA-DR mAb, PE-conjugated anti-CD80 mAb, PE-conjugated anti-CD86 mAb, PE-conjugated anti-CD138 mAb, allophycocyanin (APC)-conjugated anti-CD28, FITC-conjugated anti-CD8 mAb were purchased from Beckman Coulter; APC-conjugated anti-BDCA-1 (CD1c), APC-conjugated anti-BDCA-3 (CD141) and APC-conjugated anti-BDCA-2 (CD303), PE-conjugated anti-IL-12 mAb and PE-conjugated anti-IFN-α mAb were purchased from Miltenyi Biotec. The delta mAb SY-5, MB1 mAb SJJ-3, zeta mAb NB1, LMP2 mAb SY-1, LMP7 mAb HB2 and LMP10 mAb TO-7, calreticulin mAb TO-11 were produced and characterized as described previously 13 for different times after their isolation, depending on the assay. Prior to immunostaining of surface proteins, BMMC were cultured for 20 hours. Prior to intracellular cytokine staining, BMMC were incubated for a total of 6 hours, including 1 hour without followed by 5 hours with the secretion inhibitor Golgi Plug (1 µl/ml; BD Biosciences). For ELISA, mDC and pDC were cultured for 20 hours at which time aliquots of supernatant were removed and frozen at -80°C until batch analysis. Prior to antigen presentation assays, DC were incubated for 20
hours. To assess phagocytic activity, PKH67-labeled mDC and pDC from the same patient were pooled (to reach a suitable number of cells required for the experiments) and incubated for 20 hours with apoptotic PKH26-labeled plasma cells in the absence or presence of 10 μ g/ml of a mouse IgG1 anti-human CD91 blocking mAb (GTX79843; Genetex) or the isotype control antibody (BD Biosciences). 10 μg/ml influenza matrix 58-66 peptide (Proimmune), or 100 μg/ml autologous plasma cell lysates in 200 μl culture medium in 96-well round-bottom plates. Cells were incubated at 37°C in a humidified atmosphere containing 5% CO 2 . The medium was replaced with fresh culture medium containing 10 U/ml rIL-2 (PeproTech) on days 4, 7, 11, 14 and 18; on day 7, the fresh culture medium also contained 10 ng/ml rIL-7 (PeproTech). Cultures were restimulated with 4×10 5 irradiated autologous PBMC plus peptide or cell lysate on days 7 and 14. On day 21, cells from several wells were harvested, pooled and subjected to automated magnetic CD8 + T cell sorting. were grown in 200 µl culture medium at 37°C in a humidified atmosphere containing 5% CO 2 . Cells were harvested after 7 days and stained with epitope-specific pentamers.
Proteasome subunit expression analysis
Tumor plasma cells were incubated with or without autologous bone marrow mDC (plasma cell/DC ratio 2:1) in 96-well plates containing culture medium; some wells contained 50 μ g/ml of a mouse anti-human CD28 blocking mAb (clone CD28.6, eBioscience). In other wells, tumor plasma cells were separated from mDC by a 1 μ m pore size membrane (HTS Transwell-96 system, Corning). After 20 hours, cells were harvested, stained for CD138 and proteasome subunits, and analyzed by flow cytometry.
Cytotoxicity assay
To prepare target cells for cytotoxicity assays, CFSE-labeled tumor plasma cells were incubated alone or with bone marrow mDC, as described in the preceding section, and then 
Statistical analysis
Statistical analyses were performed using Prism (GraphPad Software). Nonparametric statistics were used because much of the data was not normally distributed. 
RESULTS
To understand the role that bone marrow DC play in the MGUS-to-MM progression, we explored a variety of features and functions of these cells from 20 patients with MGUS and 20 patients with newly diagnosed, symptomatic MM. For comparisons, we used bone marrow DC from 10 healthy controls as well as DC from peripheral blood of all three groups. First, we determined the frequencies of mDC and pDC in the peripheral blood and bone marrow of the three groups. To this aim, freshly drawn whole blood and marrow samples were stained with two different antibody cocktails (1 and 2) and analyzed by flow cytometry (Figure 1 ). 
suggest that mDC and pDC accumulate in the bone marrow during the MGUS-to-MM progression and that this accumulation is proportional to the extent of tumor burden. These results also document that the two different antibody cocktails are able to identify the same cell populations; thus, for the rest of our study, we used the cocktail 1 to label mDC and pDC.
We next examined the ability of bone marrow mDC and pDC to phagocytize apoptotic tumor plasma cells. For this purpose, both DC subsets from bone marrow were pooled (to have enough cells for the experiment) and labeled with the green membrane dye PKH67, while bone marrow CD138 + cells were labeled with the red dye PKH26 and γ-irradiated. The cell preparations were incubated together for 20 hours, after which the uptake of apoptotic cells by DC was visualized by fluorescence microscopy ( Figure 3A) and measured by flow cytometry as the percentage of doubly stained cells (Figure 3B-C) . DC from both MGUS and MM patients showed strong and comparable phagocytic activity. This activity was negligible in control samples incubated on ice (data not shown) and was drastically reduced when incubation was performed in the presence of a CD91-blocking mAb but not in the presence of an unrelated isotype control antibody (Figure 3B-C) . These results indicate that CD91 is crucial for the recognition and uptake of apoptotic tumor plasma cells by DC.
We therefore checked whether the natural CD91 ligand, i.e. calreticulin, was exposed on the surface of tumor plasma cells. To this aim, bone marrow CD138 + cells were surface-stained for calreticulin and analyzed by fluorescence microscopy ( Figure 3D ) and by flow cytometry (Figure 3E-F) . Calreticulin was found on the surface of tumor plasma cells from both MGUS and MM patients, and the percentages of stained cells were similar between the groups. These results indicate that pre-apoptotic tumor plasma cells, susceptible of being recognized and engulfed (via CD91) by DC, are present in the bone marrow of these patients.
We then assessed the co-stimulatory molecule expression and cytokine production by mDC and pDC in response to stimulation by apoptotic tumor plasma cells. To this aim, mDC and Finally, we assessed the effects that lower levels of proteasome subunits might have on the recognition of tumor plasma cells by cytotoxic T lymphocytes. To this aim, we performed flow cytometry-based cytotoxicity assays (Figure 7) . In the assays, effectors were CD8 + T cells that had been expanded in vitro in the presence of autologous DC loaded with autologous apoptotic plasma cells; targets were autologous CFSE-labeled CD138 + cells that had been pre-incubated alone or in the presence of autologous bone marrow mDC, in either normal or Transwell culture plates, with or without a CD28-blocking mAb. The tumor plasma
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Minimal specific lysis was instead observed when the plasma cells had been pre-incubated with bone marrow mDC in normal culture plates (second row). However, the cytotoxic effect was retained when the pre-incubation had been done across a Transwell insert (third row) or in normal culture plates containing a CD28-blocking mAb (fourth row). These results suggest that DC protect tumor plasma cells from CD8 + T cell killing. extends the growing evidence that calreticulin acts as a crucial "eat me signal" for DC 6, 8, 9, 30 that are equipped to perform antigen cross-presentation. Importantly, we show that this mechanism is inhibited when CD91 is blocked, thus demonstrating for the first time that the For
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The molecular link between CD28 activation and proteasome subunit downregulation remains to be determined, but it is likely to involve the PI3K/AKT pathway for several reasons: i) binding of CD28 on MM cells triggers PI3K/AKT signaling 15 ; ii) PI3K/AKT signaling induces epigenetic silencing in tumors 32, 33 ; and iii) treatment of tumor plasma cells with decitabine, a potent DNA methyltransferase inhibitor, restores proteasome subunit expression, as we have already reported 13 . Additional studies are also required to understand whether the reduced killing, by CD8 + T cells, of tumor plasma cells with lower levels of proteasome subunits is due to their decreased efficiency of epitope generation or their altered antigen repertoire.
In conclusion, we propose that DC double-cross T cells: on one hand DC activate CD8 + T cells against tumor plasma cells but, on the other hand, they nullify this activation by protecting tumor plasma cells. This knowledge has implications for the design of immunotherapy approaches that can enhance immune surveillance in MGUS and break down immune tolerance in MM. In particular, blocking CD28 interactions in vivo would prevent immune escape of tumor plasma cells and resensitize them to lysis by cytotoxic T cells. In this respect, abatacept (CTLA4-Ig), a synthetic antagonist of CD28 used for the treatment of rheumatoid arthritis 34 , could readily be moved to MM treatment. CD28 blockade would also improve the so far limited efficacy of DC-based vaccines 35 . Our in vitro findings encourage the development of these new immunotherapies.
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